Aptamer Group Reports 28% Revenue Growth and Cash Runway to 2028

Aptamer Group plc (APTA) reported financial results for the twelve months ended 30 June 2026, delivering revenue growth of 28% to £1.5 million compared to £1.2 million in the prior year. The company recorded an adjusted EBITDA loss of £2.3 million, up slightly from £2.2 million in 2025, while administrative expenses rose to £3.2 million. Cash balances reached £4.4 million at the end of June, strengthened by a £4.1 million equity fundraising completed in April 2026.

Commercial traction expanded significantly as the business secured repeat orders from global pharmaceutical leaders, including a £360,000 radioligand development deal with a major drugmaker. Aptamer also completed out-licensing agreements with Twist Bioscience and Alphazyme, receiving initial royalty payments, and deployed automated equipment to increase production capacity. The funding secured during the year extends the company's operating runway into calendar year 2028 without accounting for additional potential licensing income.

Investors should monitor the company's ongoing effort to convert recurring customer orders into multi-year master service agreements aimed at reaching EBITDA breakeven. Following the end of the financial period, Aptamer reported that its commercial pipeline grew from £4.8 million in June to £7.0 million by late September 2026. Key upcoming developments include further progress in artificial intelligence candidate validation and preclinical studies across its proprietary drug delivery programmes.